MARKET

SEEL

SEEL

Seelos Therapeutics Inc
NASDAQ
1.050
+0.020
+1.94%
After Hours: 1.050 0 0.00% 19:59 09/26 EDT
OPEN
1.020
PREV CLOSE
1.030
HIGH
1.080
LOW
1.020
VOLUME
398.78K
TURNOVER
0
52 WEEK HIGH
2.790
52 WEEK LOW
0.4803
MARKET CAP
112.03M
P/E (TTM)
-1.4968
1D
5D
1M
3M
1Y
5Y
Small Pharma, Revive Therapeutics Among Top Psychedelic Movers Of Today
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 9.91% at $0.13
Benzinga · 8h ago
Psychedelic Stock Gainers And Losers From September 22, 2022
GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 2.80% at $1.10
Benzinga · 4d ago
Psychedelic Stock Gainers And Losers From September 21, 2022
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 7.87% at $0.32
Benzinga · 5d ago
Seelos Therapeutics, Allied Among Top Psychedelic Movers Of Today
GAINERS: Allied (OTC:ALID) shares closed up 7.83% at $0.62
Benzinga · 6d ago
Psychedelic Stock Gainers And Losers From September 19, 2022
GAINERS: Cybin (AMEX:CYBN) shares closed up 5.28% at $0.65
Benzinga · 09/19 20:34
Numinus Wellness, GH Research Among Top Psychedelic Movers Of Today
GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 3.98% at $14.64
Benzinga · 09/15 20:37
GH Research, Cybin Among Top Psychedelic Movers Of Today
GAINERS: GH Research (NASDAQ:GHRS) shares closed up 9.26% at $13.81
Benzinga · 09/14 21:17
Great Psychedelics And Business Events Are Coming In Q4: Check Them Out Here
The season for psychedelics conferences is right around the corner. From very large and well-known events to small meets, this year’s remaining months are loaded with on-site and virtual discussions around the natural plant and synthetic medicines revolutionizing mental health.
Benzinga · 09/13 18:12
More
About SEEL
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of products that address unmet needs in central nervous system (CNS) disorders and other rare disorders. The Company's lead programs SLS-002 for the treatment of acute suicidal ideation and behavior (ASIB) in depressive disorder (MDD), and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS). SLS-005 for the potential treatment of Sanfilippo Syndromes, which is being explored. It is also developing several preclinical programs, including SLS-010, an oral histamine H3A receptor antagonist that shows promising activity in narcolepsy and related disorders, and SLS-012, an injectable therapy for post-operative pain management. The Company's ongoing programs include SLS-004, SLS-006, SLS-007 and SLS-008.

Webull offers kinds of Seelos Therapeutics Inc stock information, including NASDAQ:SEEL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SEEL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SEEL stock methods without spending real money on the virtual paper trading platform.